Plasma exchange and rituximab treatments in primary membranous nephropathy combined with crescentic glomerulonephritis: A case report

8Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Rationale:Crescent formation is rare in primary membranous nephropathy (MN). Anti-phospholipase A2 receptor (PLA2R) antibodies are detectable in these patients. The mechanism and treatments are unknown.Patient concerns:A 72-year-old female patient who presented with nephrotic syndrome, hematuria, and rapidly progressive kidney dysfunction.Diagnoses:Kidney biopsy was performed and the diagnosis was MN in combination with crescentic glomerulonephritis. Circulating anti-PLA2R IgG3 and IgG4 were detected of high level.Interventions:The patient received plasma exchange and rituximab besides corticosteroids.Outcomes:The patient achieved complete remission of proteinuria and recovery of kidney function after the clearance of anti-PLA2R antibodies.Lesson:This case suggests a pathogenic role of anti-PLA2R antibodies in the mechanism of crescent formation in MN, which may need intensive therapy to eliminate the antibodies quickly.

Cite

CITATION STYLE

APA

Lu, H., Cui, Z., Zhou, X. J., Jin, Q. Z., Yu, X. J., Wang, S. X., … Zhao, M. H. (2019). Plasma exchange and rituximab treatments in primary membranous nephropathy combined with crescentic glomerulonephritis: A case report. Medicine (United States), 98(18). https://doi.org/10.1097/MD.0000000000015303

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free